<?xml version='1.0' encoding='utf-8'?>
<document id="10096257"><sentence text="Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients."><entity charOffset="79-91" id="DDI-PubMed.10096257.s1.e0" text="cyclosporine" /></sentence><sentence text="The mutual drug-drug interaction potential of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin and cyclosporine (INN, ciclosporin) in kidney transplant recipients receiving individual immunosuppressive treatment was evaluated with respect to pharmacokinetic behavior of either drug and tolerability of concomitant use"><entity charOffset="118-130" id="DDI-PubMed.10096257.s2.e0" text="cerivastatin" /><entity charOffset="135-147" id="DDI-PubMed.10096257.s2.e1" text="cyclosporine" /><entity charOffset="154-165" id="DDI-PubMed.10096257.s2.e2" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.10096257.s2.e0" e2="DDI-PubMed.10096257.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10096257.s2.e0" e2="DDI-PubMed.10096257.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s2.e0" e2="DDI-PubMed.10096257.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10096257.s2.e1" e2="DDI-PubMed.10096257.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s2.e1" e2="DDI-PubMed.10096257.s2.e2" /></sentence><sentence text="" /><sentence text="Plasma and urine concentrations of cerivastatin and its major metabolites were determined after administration of 0"><entity charOffset="35-47" id="DDI-PubMed.10096257.s4.e0" text="cerivastatin" /></sentence><sentence text="2 mg single-dose cerivastatin to 12 kidney transplant recipients (9 men and 3 women) who were receiving stable individual cyclosporine treatment (mainly 200 mg twice a day)"><entity charOffset="17-29" id="DDI-PubMed.10096257.s5.e0" text="cerivastatin" /><entity charOffset="122-134" id="DDI-PubMed.10096257.s5.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.10096257.s5.e0" e2="DDI-PubMed.10096257.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10096257.s5.e0" e2="DDI-PubMed.10096257.s5.e1" /></sentence><sentence text=" These results were compared with the single-dose pharmacokinetic results obtained from a healthy control group (n = 12, age-comparable men)" /><sentence text=" Cerivastatin steady-state pharmacokinetics were evaluated in the same patients during continued immunosuppressive treatment 4 to 6 weeks later, after a 7-day treatment of 0"><entity charOffset="1-13" id="DDI-PubMed.10096257.s7.e0" text="Cerivastatin" /></sentence><sentence text="2 mg cerivastatin once a day"><entity charOffset="5-17" id="DDI-PubMed.10096257.s8.e0" text="cerivastatin" /></sentence><sentence text=" Cyclosporine steady-state concentration-time profiles were determined in blood with monoclonal (EMIT [enzyme multiplied immunoassay technique] assay, parent drug specific) and polyclonal antibodies (FPIA [fluorescence polarization immunoassay] assay, cyclosporine plus metabolites) during cerivastatin cotreatment and compared with predosing data"><entity charOffset="1-13" id="DDI-PubMed.10096257.s9.e0" text="Cyclosporine" /><entity charOffset="252-264" id="DDI-PubMed.10096257.s9.e1" text="cyclosporine" /><entity charOffset="290-302" id="DDI-PubMed.10096257.s9.e2" text="cerivastatin" /><pair ddi="false" e1="DDI-PubMed.10096257.s9.e0" e2="DDI-PubMed.10096257.s9.e0" /><pair ddi="false" e1="DDI-PubMed.10096257.s9.e0" e2="DDI-PubMed.10096257.s9.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s9.e0" e2="DDI-PubMed.10096257.s9.e2" /><pair ddi="false" e1="DDI-PubMed.10096257.s9.e1" e2="DDI-PubMed.10096257.s9.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s9.e1" e2="DDI-PubMed.10096257.s9.e2" /></sentence><sentence text="" /><sentence text="Coadministration of 0" /><sentence text="2 mg cerivastatin once a day to the kidney transplant recipients treated with individual doses of cyclosporine and other immunosuppressive agents resulted in a 3- to 5-fold increase in cerivastatin and metabolites plasma concentrations"><entity charOffset="5-17" id="DDI-PubMed.10096257.s12.e0" text="cerivastatin" /><entity charOffset="98-110" id="DDI-PubMed.10096257.s12.e1" text="cyclosporine" /><entity charOffset="185-197" id="DDI-PubMed.10096257.s12.e2" text="cerivastatin" /><pair ddi="false" e1="DDI-PubMed.10096257.s12.e0" e2="DDI-PubMed.10096257.s12.e0" /><pair ddi="false" e1="DDI-PubMed.10096257.s12.e0" e2="DDI-PubMed.10096257.s12.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s12.e0" e2="DDI-PubMed.10096257.s12.e2" /><pair ddi="false" e1="DDI-PubMed.10096257.s12.e1" e2="DDI-PubMed.10096257.s12.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s12.e1" e2="DDI-PubMed.10096257.s12.e2" /></sentence><sentence text=" Cerivastatin and metabolites elimination half-lives were unaffected, and no accumulation occurred during multiple-dosing conditions"><entity charOffset="1-13" id="DDI-PubMed.10096257.s13.e0" text="Cerivastatin" /></sentence><sentence text=" Cerivastatin had no influence on steady-state blood concentrations of cyclosporine or cyclosporine metabolites in these patients"><entity charOffset="1-13" id="DDI-PubMed.10096257.s14.e0" text="Cerivastatin" /><entity charOffset="71-83" id="DDI-PubMed.10096257.s14.e1" text="cyclosporine" /><entity charOffset="87-99" id="DDI-PubMed.10096257.s14.e2" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.10096257.s14.e0" e2="DDI-PubMed.10096257.s14.e0" /><pair ddi="false" e1="DDI-PubMed.10096257.s14.e0" e2="DDI-PubMed.10096257.s14.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s14.e0" e2="DDI-PubMed.10096257.s14.e2" /><pair ddi="false" e1="DDI-PubMed.10096257.s14.e1" e2="DDI-PubMed.10096257.s14.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s14.e1" e2="DDI-PubMed.10096257.s14.e2" /></sentence><sentence text=" The concomitant use of both drugs was well tolerated" /><sentence text="" /><sentence text="Cerivastatin and metabolites plasma concentrations were significantly increased in kidney transplant recipients treated with cyclosporine and other immunosuppressive agents"><entity charOffset="0-12" id="DDI-PubMed.10096257.s17.e0" text="Cerivastatin" /><entity charOffset="125-137" id="DDI-PubMed.10096257.s17.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.10096257.s17.e0" e2="DDI-PubMed.10096257.s17.e0" /><pair ddi="false" e1="DDI-PubMed.10096257.s17.e0" e2="DDI-PubMed.10096257.s17.e1" /></sentence><sentence text=" Displacement from the main site for cerivastatin distribution-the liver-by cyclosporine-inhibited liver transport processes may explain the decrease in both metabolic clearance and volume of distribution for cerivastatin and metabolites"><entity charOffset="37-49" id="DDI-PubMed.10096257.s18.e0" text="cerivastatin" /><entity charOffset="76-88" id="DDI-PubMed.10096257.s18.e1" text="cyclosporine" /><entity charOffset="209-221" id="DDI-PubMed.10096257.s18.e2" text="cerivastatin" /><pair ddi="false" e1="DDI-PubMed.10096257.s18.e0" e2="DDI-PubMed.10096257.s18.e0" /><pair ddi="false" e1="DDI-PubMed.10096257.s18.e0" e2="DDI-PubMed.10096257.s18.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s18.e0" e2="DDI-PubMed.10096257.s18.e2" /><pair ddi="false" e1="DDI-PubMed.10096257.s18.e1" e2="DDI-PubMed.10096257.s18.e1" /><pair ddi="false" e1="DDI-PubMed.10096257.s18.e1" e2="DDI-PubMed.10096257.s18.e2" /></sentence><sentence text="" /></document>